Every 10-Q that Guardian Pharmacy Services, Inc. (GRDN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRDN filings page.
Guardian Pharmacy Services, Inc. reported solid growth for the three and six months ended June 30, 2026. Q2 2026 revenue was $351,768 (in thousands), up 2.2% year over year, while net income attributable to the company rose to $21,872 (in thousands) from $9,030 (in thousands). Diluted EPS increased to $0.34 from $0.14. Adjusted EBITDA for Q2 grew to $29,658 (in thousands), or 8.4% of revenue.
Results were shaped by 2025 acquisitions and U.S. Inflation Reduction Act (IRA) drug pricing, which reduced organic revenue but more sharply lowered product costs, improving gross margin from 19.8% to 22.8%. Residents served increased from 195,000 to 210,000, and Q2 prescriptions dispensed rose from 7.0 million to 7.6 million.
The company recorded an $8.5 million cash gain from a payor-reimbursement settlement, boosting other income. Liquidity remained strong with $89,807 (in thousands) of cash and cash equivalents and no borrowings outstanding on a $40 million revolving credit facility that now matures in 2030, with the option to expand total capacity to $80 million.
Guardian Pharmacy Services, Inc. reported solid Q1 2026 growth, with revenue rising to $336.6M from $329.3M, a 2.2% increase. Net income grew to $13.5M from $9.3M, and diluted EPS rose to $0.21 from $0.15, reflecting margin expansion.
Cost of goods sold fell to $260.3M, or 77.3% of revenue, helped by lower product costs under the Inflation Reduction Act, lifting gross profit to $76.3M. Adjusted EBITDA increased to $29.8M, or 8.8% of revenue.
The company ended March 31, 2026 with $64.9M in cash and no borrowings under its $40M credit facility. It also converted 13.5M Class B shares into Class A and executed a Q1 2026 follow-on offering in which 1.02M Class A shares were sold and repurchased for cancellation without changing shares outstanding.
Guardian Pharmacy Services (GRDN) reported stronger Q3 results. Revenue rose to $377.4 million, up 20% from $314.4 million a year ago, as the company served more residents and filled more prescriptions. Gross profit reached $74.7 million. Selling, general and administrative costs dropped to $58.4 million, reflecting much lower share-based compensation versus the 2024 IPO period.
Operating income was $16.4 million compared with a loss last year. Net income was $9.6 million, with diluted EPS of $0.15; for the first nine months, net income was $27.7 million and diluted EPS was $0.45. Cash and cash equivalents were $36.5 million, up from $4.7 million at year-end. The business served about 204,000 residents across roughly 8,200 long‑term care facilities in 38 states as of September 30, 2025.
In 2025, the company completed acquisitions with total preliminary consideration of $16.3 million, contributing $16.2 million of Q3 revenue. Interest expense declined as there were no outstanding balances under the credit facility during the period.
Guardian Pharmacy Services, Inc. reported second-quarter 2025 revenue of $344.3 million (up 14.8% year-over-year) and year-to-date revenue of $673.6 million (up 17.1%). The company served about 195,000 residents across 52 pharmacies and dispensed 7.0 million prescriptions in the quarter, driving organic and acquisition-backed growth.
Quarterly net income was $8.8 million (six-month net income $18.1 million), below the prior-year comparable periods of $15.8 million and $22.9 million, respectively. Cost of goods sold increased as a percentage of revenue to 80.2% in Q2 2025, and selling, general and administrative expense rose to $55.6 million (16.1% of revenue), driven by higher headcount and share-based compensation. Adjusted EBITDA improved to $48.4 million for the six months ended June 30, 2025 (from $41.9 million).
The company completed an IPO and a follow-on offering that generated net proceeds of $119.8 million from the IPO and used proceeds from the follow-on to repurchase and cancel 1,440,447 Class A shares. Cash and cash equivalents increased to $18.8 million. Management completed multiple acquisitions (2025 preliminary purchase consideration of $11.1 million with $6.9 million of goodwill recorded).